Generation and Characterization of a Defective HIV-1 Virus as an Immunogen for a Therapeutic Vaccine

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Álvarez Fernández, Carmen ^a   Crespo Guardo, Alberto ^a   García Pérez, Javier ^b   García, Felipe ^a   Blanco, Julia ^c   Escribà García, Laura ^a   Gatell, Jose Maria ^a   Alcamí, Jose ^b   Plana, Montserrat ^a   Sánchez Palomino, Sonsoles ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Institut de Recerca de la Sindrome de Inmunodeficencia Adquirida   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' DITHIODIPYRIDINE; AMPRENAVIR; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ARTICLE; ASYMPTOMATIC INFECTION; BASE PAIRING; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEFECTIVE VIRUS; DRUG SAFETY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELETION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NONHUMAN; STRUCTURAL GENE; VIRION; VIRUS CELL INTERACTION; VIRUS CORE; VIRUS GENOME; VIRUS INACTIVATION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE; WILD TYPE;

AIDS VACCINES; COHORT STUDIES; HEK293 CELLS; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; SEQUENCE DELETION; VIRION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84868687829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048848     Document Type: Article

References (76)

1. Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L, (2010) Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis 10: 305-316.
2. Lakhashe SK, Silvestri G, Ruprecht RM, (2011) No Acquisition: a New Ambition for HIV Vaccine Development? Curr Opin Virol 1: 246-253.
3. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, et al. (2002) Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 169: 4778-4787.
4. Letvin NL, Walker BD, (2003) Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 9: 861-866.
5. Libois A, Lopez A, Garcia F, Castro P, Maleno MJ, et al. (2006) Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses 22: 657-666.
6. Igarashi T, Endo Y, Englund G, Sadjadpour R, Matano T, et al, (1999) Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. Proc Natl Acad Sci U S A 96: 14049-14054.
7. Freel SA, Saunders KO, Tomaras GD, (2011) CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Immunologic research 49: 135-146.
8. Chhatbar C, Mishra R, Kumar A, Singh SK, (2011) HIV vaccine: hopes and hurdles. Drug Discov Today 16: 948-56.
9. McElrath MJ, Haynes BF, (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
10. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S, (2000) Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549×10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 284: 2193-2202.
11. Desrosiers RC, Hansen-Moosa A, Mori K, Bouvier DP, King NW, et al. (1991) Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS. Am J Pathol 139: 29-35.
12. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, et al. (1999) Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73: 8356-8363.
13. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, et al. (2009) Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15: 901-906.
14. Gundlach BR, Lewis MG, Sopper S, Schnell T, Sodroski J, et al. (2000) Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. 74: 3537-3542.
15. Das AT, Jeeninga RE, Berkhout B, (2010) Possible applications for replicating HIV 1 vectors. HIV Ther 4: 361-369.
16. Kestler HW 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, et al (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651-662.
17. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, et al. (1997) Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229: 143-154.
18. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC, (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941.
19. Verhoef K, Marzio G, Hillen W, Bujard H, Berkhout B, (2001) Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J Virol 75: 979-987.
20. Evans DT, Bricker JE, Sanford HB, Lang S, Carville A, et al. (2005) Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J Virol 79: 7707-7720.
21. Smith SM, Markham RB, Jeang KT, (1996) Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function. Proc Natl Acad Sci U S A 93: 7955-7960.
22. Falkensammer B, Rubner B, Hiltgartner A, Wilflingseder D, Stahl Hennig C, et al. (2009) Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors. Retrovirology 6: 60.
23. Gorry PR, McPhee DA, Verity E, Dyer WB, Wesselingh SL, et al. (2007) Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology 4: 66.
24. Liu Z, Singh DK, Sheffer D, Smith MS, Dhillon S, et al. (2006) Immunoprophylaxis against AIDS in macaques with a lentiviral DNA vaccine. Virology 351: 444-454.
25. Singh DK, Liu Z, Sheffer D, Mackay GA, Smith M, et al. (2005) A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. J Virol 79: 3419-3428.
26. Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, (2011) Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine 29: 4903-4912.
27. Larsson M, Fonteneau JF, Bhardwaj N, (2003) Cross-presentation of cell-associated antigens by dendritic cells. Curr Top Microbiol Immunol 276: 261-275.
28. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
29. Garcia F, Leon A, Gatell JM, Plana M, Gallart T, (2012) Therapeutic vaccines against HIV infection. Human vaccines & immunotherapeutics 8: 569-581.
30. Kovacsovics-Bankowski M, Rock KL, (1995) A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267: 243-246.
31. Rock KL, Clark K, (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. Journal of immunology 156: 3721-3726.
32. Garcia F, Routy JP, (2011) Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 29: 6454-6463.
33. Lu W, Arraes LC, Ferreira WT, Andrieu JM, (2004) Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10: 1359-1365.
34. Garcia F, Climent N, Assoumou L, Gil C, Gonzalez N, et al. (2011) A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 203: 473-478.
35. Routy J, Angel J, Vezina S, Tremblay C, Loutfy M, et al. (2011) Final Analysis of a Phase 2 Study of an Autologous DC Immunotherapy (AGS-004) Showed Positive Outcomes in Primary Endpoint of Viral Load Control, and Favorable Safety and Immunogenicity Profile, in Subjects Undergoing Structured Treatment Interruption of ART (abstract 385). In 18th Conference on Retroviruses and Opportunistic Infections. Boston.
36. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, et al. (2005) Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 191: 1680-1685.
37. Moore MD, Fu W, Soheilian F, Nagashima K, Ptak RG, et al. (2008) Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation. Virology 379: 152-160.
38. Volberding PA, Deeks SG, (2010) Antiretroviral therapy and management of HIV infection. Lancet 376: 49-62.
39. Gamble LJ, Matthews QL, (2011) Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther 5: 9-26.
40. Khorchid A, Javanbakht H, Wise S, Halwani R, Parniak MA, et al. (2000) Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1. J Mol Biol 299: 17-26.
41. Cen S, Niu M, Kleiman L, (2004) The connection domain in reverse transcriptase facilitates the in vivo annealing of tRNALys3 to HIV-1 genomic RNA. Retrovirology 1: 33.
42. Saadatmand J, Guo F, Cen S, Niu M, Kleiman L, (2008) Interactions of reverse transcriptase sequences in Pol with Gag and LysRS in the HIV-1 tRNALys3 packaging/annealing complex. Virology 380: 109-117.
43. Kleiman L, Jones CP, Musier-Forsyth K, et al. (2010) Formation of the tRNALys packaging complex in HIV-1. FEBS Lett 584: 359-365.
44. Lifson JD, Rossio JL, Piatak M Jr, Parks T, Li L, et al. (2001) Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 75: 10187-10199.
45. Rodriguez-Plata MT, Urrutia A, Cardinaud S, Buzon MJ, Izquierdo-Useros N, et al. (2012) HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T cell activation. Journal of immunology 188: 6036-6045.
46. Michelini Z, Negri DR, Baroncelli S, Spada M, Leone P, et al. (2009) Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine 27: 4622-4629.
47. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, et al. (2010) Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143: 789-801.
48. Rutebemberwa A, Bess JW Jr, Brown B, Arroyo M, Eller M, et al. (2007) Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses. AIDS Res Hum Retroviruses 23: 532-542.
49. Ganser-Pornillos BK, Yeager M, Sundquist WI, (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18: 203-217.
50. Muller B, Anders M, Akiyama H, Welsch S, Glass B, et al. (2009) HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem 284: 29692-29703.
51. de Marco A, Muller B, Glass B, Riches JD, Krausslich HG, et al. (2010) Structural analysis of HIV-1 maturation using cryo-electron tomography. PLoS Pathog 6: e1001215.
52. Chiang CC, Tseng YT, Huang KJ, Pan YY, Wang CT, (2012) Mutations in the HIV-1 reverse transcriptase tryptophan repeat motif affect virion maturation and Gag-Pol packaging. Virology 422: 278-287.
53. Ohishi M, Nakano T, Sakuragi S, Shioda T, Sano K, et al. (2011) The relationship between HIV-1 genome RNA dimerization, virion maturation and infectivity. Nucleic acids research 39: 3404-3417.
54. Wagner R, Fliessbach H, Wanner G, Motz M, Niedrig M, et al. (1992) Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch Virol 127: 117-137.
55. Hallengard D, Haller BK, Petersson S, Boberg A, Maltais AK, et al. (2010) Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29: 839-848.
56. Joyner AS, Willis JR, Crowe JE Jr, Aiken C, (2011) Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog 7: e1002234.
57. Fonteneau JF, Kavanagh DG, Lirvall M, Sanders C, Cover TL, et al. (2003) Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 102: 4448-4455.
58. Moron VG, Rueda P, Sedlik C, Leclerc C, (2003) In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 171: 2242-2250.
59. Larsson M, Fonteneau JF, Lirvall M, Haslett P, Lifson JD, et al. (2002) Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS 16: 1319-1329.
60. Larsson M, Wilkens DT, Fonteneau JF, Beadle TJ, Merritt MJ, et al. (2002) Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. AIDS 16: 171-180.
61. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, et al. (2005) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. Journal of virology 79: 1154-1163.
62. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
63. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284-291.
64. Garcia-Perez J, Perez-Olmeda M, Sanchez-Palomino S, Perez-Romero P, Alcami J, (2008) A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV Med 9: 160-171.
65. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
66. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
67. Takeuchi Y, McClure MO, Pizzato M, (2008) Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82: 12585-12588.
68. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
69. Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, Alcami J, (2007) A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol 79: 127-137.
70. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, et al. (1998) Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 72: 7992-8001.
71. Lopez-Iglesias C, Puvion-Dutilleul F, (1988) Effects of tunicamycin and monensin on the distribution of highly phosphorylated proteins in cells infected with herpes simplex virus type 1. J Ultrastruct Mol Struct Res 101: 173-184.
72. Lopez-Iglesias C, Puvion-Dutilleul F, (1988) Visualization of glycoproteins after tunicamycin and monensin treatment of herpes simplex virus infected cells. J Ultrastruct Mol Struct Res 101: 75-91.
73. Lopez-Iglesias C, Puvion-Dutilleul F, Cebrian J, Christensen ME, (1988) Herpes simplex virus type 1-induced modifications in the distribution of nucleolar B-36 protein. Eur J Cell Biol 46: 259-269.
74. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
75. Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, et al. (2004) Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr 36: 791-799.
76. Lopez A, van der Lubbe N, Sanchez-Palomino S, Arnedo M, Nomdedeu M, et al. (2009) Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine 27: 6166-6178.